US-facing commercial architecture for Geneva single and multi-family offices, private-banking principals, and family-office-backed biotech, medtech, and engineering-commercial holdings now deploying capital into US co-investment, portfolio-company commercialisation, or direct US platform activity. Geneva discretion carries standing on Quai du Mont-Blanc and across the Romandie wealth tier. It does not travel to the American private banker, US family-office peer, or US co-investor reading the same materials in New York, Boston, or San Francisco.
The family office has built standing in Geneva over a generation or longer through the Quai du Mont-Blanc private-banking tier, external-asset-manager relationships, and quiet compounding across Romandie structures, Lake Geneva real assets, and a portfolio that often includes biotech and medtech holdings inside the Lonza and Novartis-adjacent ecosystem. The name carries among Swiss and European peers. Governance is clean. Discretion is total. Then a US co-investment vehicle forms, a portfolio biotech approaches the US clinical and commercial threshold, a US family-office peer asks for materials, or an American general partner requests a meeting.
The gap surfaces in the first exchange. US intermediaries, American private bankers, US family-office peers, and US general partners read Geneva discretion as category absence rather than depth. Holding-brand collateral built for a Romandie audience that already knows the family arrives on the desk of a New York or Boston reader who does not. The absence of a US category anchor, a US outcome claim, and a US peer set leaves the American frame empty. The reader fills the empty frame with Swiss stereotypes or with nothing at all, and the conversation loses momentum before the governance and the thesis can carry weight.
The instinct is to produce more polished Quai du Mont-Blanc-tier collateral, or to fold the portfolio biotech further into the family narrative for credibility. Both instincts deepen the problem. What the US intermediary needs is two clear public layers that do different jobs, with the seam between them visible, and an operating brand that leads with a US category claim before Geneva origin sits as one supporting fact rather than the dominant one.
The American co-investor is not evaluating the Geneva family. They are trying to locate the company. Geneva discretion and holding-brand overflow have made that harder than it should be. House view on Geneva family-office positioning
The family office is not the problem. The portfolio is not the problem. The two surfaces are doing each other's job, and Geneva discretion is filling the frame the US category claim should have occupied.
Six to ten weeks. Single US category or single portfolio company. The firm rebuilds positioning, pricing posture, messaging, and trust architecture for the American co-investor, private banker, or US buyer, then launches it into market.
See the Sprint →Three to six months. Holding-brand and operating-brand surfaces rebuilt together, with the seam between them defined and visible. Typical when a US co-investment closes or a Geneva-held portfolio-company US rollout is imminent.
See the Build →Monthly retainer, twelve-month minimum. Ongoing rebuild-and-run across the holding brand and several portfolio-company surfaces. Standard shape for Geneva family offices with multiple US-facing brands or co-investment positions in play.
See the Partnership →No legal services. No Swiss company formation or US entity formation. No SFO or MFO structure design. No foundation, trust, or SPV setup. No FINMA licensing, EB-5, E-2, L-1, or O-1 visa work. No US tax structuring, FATCA analysis, CRS analysis, or double-tax-treaty review. No US banking introductions. No fiduciary services. No regulatory licensing. No clinical strategy, IND filing, or US reimbursement-pathway design. No IP filing. No contract drafting.
These belong with Geneva counsel who specialise in family-office structuring and US entry, with US counsel on the American side, and with clinical and regulatory specialists where biotech and medtech work is in scope. The firm works inside the parameters they set. When a marketing decision carries legal, tax, fiduciary, clinical, or regulatory implications, the firm flags it and defers before execution.
The two cities sit inside the same Swiss frame and read as one to a US audience that is unfamiliar with the distinction. The differences matter on the ground. Geneva carries a deeper private-banking and wealth-management heritage, a heavier concentration of multi-family-office and external-asset-manager structures, and a larger Romandie-tier biotech and medtech footprint connected to the Geneva-Lausanne corridor and the Lonza and Novartis-adjacent ecosystem. Zurich carries the Paradeplatz private-banking core and a different industrial-Mittelstand mix. The commercial pattern that breaks for both audiences in front of US intermediaries is the same: Swiss discretion reads as category absence, holding brand and operating brand collapse into one surface, and CHF-denominated track records do not convert. The work is calibrated to the city, the structure, and the portfolio, not delivered as a generic Swiss template.
Family-office-backed biotech connected to the Geneva-Lausanne corridor and the Lonza and Novartis-adjacent base, family-office-backed medtech, engineering-commercial holdings, premium services holdings inside Geneva and Vaud structures, and portfolio-company US commercialisation. The pattern is consistent across these sectors: the US category anchor is missing, the US peer set is absent, the holding brand bleeds into the operating brand, and Romandie-register understatement fills hero positions where US readers expect outcome claims. Fit is confirmed in discovery, not in published sector lists.
Yes. A common arrival route is a Geneva private-client lawyer, tax advisor, trust officer, external asset manager, or multi-family-office principal introducing a structure whose holding entity is about to deploy capital into US co-investment or US platform-building. The fiduciary retains the principal relationship. The firm designs the US-facing commercial architecture inside the structure the fiduciary already manages. Fiduciary introductions route through partnerships@globalmarketing.agency.
Yes. The Geneva corridor covers Lausanne, EPFL-spinout, and Vaud-based biotech and medtech principals whose pipeline assets and IP are strong enough for US commercialisation but whose US-facing positioning does not yet land with US investors, KOLs, or payers. The work addresses the same register problem: academic-rigour bios anchored to EPFL, the University of Geneva, or the University Hospitals of Geneva, CHF-indexed track records, and Romandie-tier understatement filling the hero where a US category claim and a US peer set belong.
With an inquiry through the contact form and a short discovery conversation. The firm runs three engagements: Market Entry Sprint (six to ten weeks), Cross-Border Build (three to six months), or Group Partnership (monthly retainer, twelve-month minimum). Fit and pricing are confirmed in discovery, not published. Family-office engagements most often begin as a Build or Partnership because the holding brand and several portfolio surfaces are typically in scope at once.
The wider Geneva entry gate for family offices, fiduciaries, and Romandie biotech, medtech, and engineering-commercial principals moving into the United States.
See the Geneva gate →The Riviera-side counterpart. Monaco family offices and US co-investment activity, with a heavier residency-driven holding profile and a lighter operating-company footprint than Geneva.
See Monaco family offices →Market Entry Sprint, Cross-Border Build, Group Partnership. Family-office engagements most often begin as a Build or Partnership.
See the engagements →